30 results about "Y nucleoside" patented technology

The present invention relates to 2′-allene-substituted nucleoside derivatives of the general formula (I):As well as pharmaceutical compositions comprising such compounds and methods to treat or prevent an HIV infection, HBV infection, HCV infection or abnormal cellular proliferation, comprising administering said compounds or compositions. In addition, the present invention includes processes for the preparation of such compounds, and the related β-D and β-L-nucleoside derivatives.

The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.

The invention relates to the use of bicyclic nucleosides and nucleotides based on formula (II) for the treatment of infectious diseases, and in particular, viral infections.

The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and / or nucleoside hydrolases (NH). The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and / or nucleoside hydrolases (NH).

[Problems] A derivative of a nucleic acid antimetabolite is demanded which can show a high therapeutic effect at a low dose.[Means For Solving Problems] Disclosed is a high molecular weight derivative of a nucleic acid antimetabolite, which is characterized by comprising a high molecular weight compound comprising a polyethylene glycol moiety and a polymer moiety having a carboxyl group in a side chain and a nucleoside derivative which can act as a nucleic acid antimetabolite, wherein the carboxyl group in the side chain is bound to a hydroxyl group in the nucleoside derivative via an ester bond. Also disclosed is a method for producing the high molecular weight derivative.

The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and / or nucleoside hydrolases (NH). The present invention relates to a new process for the preparation of compounds of general formula (I) which are inhibitors of purine nucleoside phosphorylases (PNP), purine phosphoribosyltransferases (PPRT), 5′-methylthioadenosine phosphorylases (MTAP), 5′-methylthioadenosine nucleosidases (MTAN) and / or nucleoside hydrolases (NH).

Compositions and methods for modulating the activity of RNA are disclosed. In accordance with preferred embodiments, antisense compositions are prepared comprising targeting and reactive portions. The reactive portions preferably comprise one or two imidazole functionalities conjugated to the targeting oligonucleotide via linkers with or without intervening intercalating moieties. Therapeutics, diagnostics and research methods also are disclosed, as are synthetic nucleosides and nucleoside fragments that can be elaborated into oligonucleotides.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether.

Provided herein are methods of treating a proliferative disease in a subject, comprising administering to the subject a therapeutically effective amount of AC220 and a nucleoside analog, a topoisomerase inhibitor or an anthracycline, or a combination thereof.

Disclosed is an RNA aptamer, a synthetic oligonucleotide of 2′-fluoro-modified A, U, and C nucleotides, with improved stability compared to its unmodified counterpart. Like the unmodified aptamer, however, the modified version is a potent glutamate receptor antagonist. Additionally, the RNA aptamers described herein are water soluble by nature, and generally exhibit nano- to micromolar potency making them potential therapeutic agents for the treatment of neurological disorders involving glutamate receptor activity.

The invention discloses a method for determining the content of alkaloids, lignans and nucleosides in Radix isatidis or its preparation by adopting a one-measurement multi-evaluation method. , S)-Yichun is used as a reference to establish its relative correction factor with the lignan compound tetracycline B and the nucleoside compounds cytidine, uridine, guanosine, and adenosine, to achieve by measuring only The content of (R,S)-report Yichun of Radix Isatidis or its preparations, the content of the other 5 kinds of lignans and nucleosides with higher content was calculated by the correction factor, so as to be simple, quick, comprehensive and accurate. The multi-index quality evaluation of its preparation is helpful to ensure the quality of the product is controllable and the curative effect is stable, while saving the testing cost and time.

The invention discloses rare-earth nucleoside fluorescent hydrogel as well as a preparation method and application thereof in fluorescent encoding. The preparation method of the rare-earth nucleosidefluorescent hydrogel comprises the following steps: (1) preparing a soluble rare-earth nitrate water solution and a nucleoside water solution; (2) uniformly mixing the soluble rare-earth nitrate watersolution and the nucleoside water solution and regulating the pH (Potential of Hydrogen) value to 7 to 9; raising the temperature to 55 to 95 DEG C and standing and reacting for 10 to 20min; coolingto room temperature and standing for 1 to 4h to obtain the rare-earth nucleoside fluorescent hydrogel with different fluorescent colors. The rare-earth nucleoside fluorescent hydrogel disclosed by theinvention has the advantages of environment-friendly and safe raw materials, simplicity in operation, low cost and good repeatability; the rare-earth nucleoside fluorescent hydrogel disclosed by theinvention keeps characteristic of emission fluorescent light of rare-earth ions and also has characteristics of good biocompatibility of biological small molecular nucleoside, biodegradability, no toxicity and the like. The obtained fluorescent hydrogel is regulated and controlled to obtain various fluorescent colors and can be used as a fluorescent encoding material; the fluorescent hydrogel canbe used for fluorescent biological detection, cell culture and tissue engineering.

The present invention pertains to: an alkoxyphenyl derivative with which oligonucleotides can by synthesized by a liquid-phase synthesis method easier and faster than conventional methods; a nucleoside protector and a nucleotide protector to which the alkoxyphenyl derivative binds; a method for producing an oligonucleotide using same; and a method for selectively removing the alkoxyphenyl derivative moiety. Provided is a compound represented by general formula (1) or a derivative thereof. (In the formula, each R independently represents a C10-40 alkyl group which may be substituted or unsubstituted. m represents an integer of 1-5. When m is 2 or more, the plurality of RO's may be identical or different. X represents O, S, NH, or NRN. n represents an integer of 1-4. RN represents a C1-6 alkyl group which may be substituted or unsubstituted.).